

KRAS MUTATION, CODON 12 & 13

KRAS MUTATION, CODON 12 & 13

(PCR, Fragment Analysis)

Detected / Not detected

Codon 12 Mutation

Detected / Not detected

Codon 13 Mutation

Note:

1. This result does not rule out the presence of mutation that may be below the detection limits of the assay
2. Predictive value of KRAS mutation detection applies only to EGFR targeted therapies and not to other therapeutic agents
3. Discordant results may be obtained in 10% of cases
4. For Research purposes only. Results to be interpreted in context of clinical findings, tumor sampling and other laboratory data.

Comments

KRAS mutation testing is recommended prior to initiation of EGFR targeted therapy in Colorectal carcinoma. Efficacy of EGFR targeted therapy such as Cetuximab and Panitumumab in Colon cancer is confined to patients lacking KRAS mutations. Absence of detectable KRAS mutation within the tumor specimen tested suggests that this patient may respond to such therapies.